BlueWillow Biologics Names Leading Viral Infectious Disease Experts to Scientific Advisory Board
Retrieved on:
Tuesday, September 21, 2021
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Novartis Institute for Tropical Diseases, Therapy, Infection, Vertically transmitted infection, Developmental Biology (journal), Vaccine, SAB, Howard Hughes Medical Institute, Merck & Co., National, University, Coronavirus Scientific Advisory Board (Turkey), Wyeth, Virus, Senior, Immunology, Merck, Company, LLC, Columbia University, Biological Technologies Office (DARPA), COVID-19, Research, Anthrax, RSV, Degenerative disease, International Medical Education Directory, Food, Massachusetts Institute of Technology, Waldemar von Zedtwitz, Urinary tract infection, Biomedical Research, HSV, MedImmune, Massachusetts, Department, Pharmaceutical industry
BlueWillow Biologics, Inc. , a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, today announced the formation of the Company's Scientific Advisory Board (SAB) with three leading viral infectious disease experts.
Key Points:
- BlueWillow Biologics, Inc. , a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, today announced the formation of the Company's Scientific Advisory Board (SAB) with three leading viral infectious disease experts.
- The members of the BlueWillow Biologics SAB include:
Robin Isaacs, M.D. - Prior, he held positions of increasing responsibility at Merck & Co., Inc., most recently serving as Vice President and Therapeutic Area Head, Vaccine Clinical Research.
- We are proud to have such a distinguished team of scientific experts serve as members of our Scientific Advisory Board, underscoring their belief in our intranasal vaccines to elicit mucosal immunity, commented Chad Costley, M.D., President and Chief Executive Officer of BlueWillow Biologics.